NCT04890535已完成1 期
Phase 1, Partially Blinded, Placebo-Controlled, Randomized, Combined Single Ascending Dose With Food Effect Cohort Trial and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and PK of TBAJ-587 in Healthy Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 106
- 试验地点
- 1
- 主要终点
- Number of Participants with Treatment-Related Adverse Events in the Single Ascending Dose (SAD) population
研究概览
简要总结
Phase 1, Partially Blinded, Placebo-Controlled, Randomized, Combined Single Ascending Dose with Food Effect Cohort Trial (Part 1) and Multiple Ascending Dose Trial (Part 2) to Evaluate the Safety, Tolerability, and PK of TBAJ-587 in Healthy Adults
详细描述
This is a two-part, partially blinded, placebo-controlled, combined single ascending dose (SAD) trial with a food-effect cohort (Part 1) and multiple ascending dose (MAD) trial (Part 2) to be conducted in one trial centre in Europe.
Part 1: Has a single ascending dose (SAD) design with up to 6 planned dose levels with a food-effect cohort at one of the dose levels.
The first SAD cohort will be separated into 2 groups. A sentinel group of two participants (1 active and 1 placebo) will be dosed at least 72 hours before the remaining 6 participants (5 active and 1 placebo). The other cohorts will not be separated.
Other Dose Level cohorts: scheduling of safety and PK sample collection will be based on the PK data collected from previous cohorts.
Food-Effect Cohort: Based on exposure levels from preceding SAD cohorts, one of the planned cohorts and the specific dose will be selected for the food effect (FE) cohort which will study the effect on PK after a high-calorie, high-fat meal. Additional participants will be recruited to reach a total of 9 active participants, inclusive of the previously dosed participants, in the fasted group, and 9 additional active participants will be recruited for the group dosed with food.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants are required to meet all the following inclusion criteria to be eligible for participation in the trial:
- •Provide written, informed consent prior to all trial-related procedures.
- •Healthy adult male and females of non-childbearing potential, 18-64 years of age (inclusive) at the time of screening.
- •Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) and a body weight of no less than 50.0 kg.
- •Medically healthy with no clinically significant screening results (e.g., laboratory profiles normal or up to Grade 1 per FDA Toxicity Grading Scale), medical histories, vital signs, ECGs, physical examination findings, as deemed by the Investigator. Lab results within the testing facilities normal range will not be considered AEs when referenced to the FDA (Appendix 2) assessment/grading scale. If exclusionary lab criteria are met, values may be confirmed by repeat evaluation.
- •No use of tobacco or nicotine containing products (including smoking cessation products), for a minimum of 6 months prior to dosing.
- •Females of non-childbearing potential, having undergone one of the following sterilization procedures at least 6 months prior to dosing:
- •Hysteroscopic sterilization
- •Bilateral tubal ligation or bilateral salpingectomy
- •Hysterectomy
- •Bilateral oophorectomy or be postmenopausal with amenorrhea for at least 1 year prior to the first dose with serum
- •Follicle-stimulating hormone (FSH) levels consistent with postmenopausal status at screening.
- •Non-vasectomized males (or males vasectomized less than 120 days prior to trial start), must agree to the following during trial participation and for 90 days following the last administration of trial drug:
- •Use a condom with spermicide while engaging in sexual activity or be sexually abstinent
- •Not donate sperm during this time.
- •In the event the sexual partner is surgically sterile, use of a condom with spermicide is not necessary.
- •None of the restrictions listed above are required for vasectomized males whose procedure was performed more than 120 days prior to trial start.
- •Willing to answer inclusion and exclusion criteria questionnaire at check-in.
- •Participant understands trial procedures and provides written informed consent for the trial.
- •Be able to comply with the protocol and the assessments therein, including all restrictions.
- •Is willing and able to remain in the trial unit for the entire duration of the assigned confinement period and return for outpatient visits.
- •If enrolled in Part 1 and assigned to the fasted/fed cohort, is willing and able to consume the entire high-calorie, high-fat breakfast meal in the timeframe required.
- •Has negative Quantiferon test during the screening. -
排除标准
- •Participants will be excluded from the trial if there is evidence of any of the following criteria at screening or check-in, as appropriate.
- •History or presence of significant cardiovascular abnormalities, Heart Murmur, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease as determined by the Investigator to be clinically relevant.
- •Any musculoskeletal abnormality (severe tenderness with marked impairment of activity) or musculoskeletal toxicity (frank necrosis).
- •History of any illness that, in the opinion of the Investigator, might confound the results of the trial or poses an additional risk to the participant by their participation in the trial.
- •Surgery within the past 90 days prior to dosing or other previous surgery as determined by the Investigator to be clinically relevant.
- •History or presence of alcoholism or drug abuse within the past 2 years as determined by the Investigator to be clinically relevant.
- •Female participants who are pregnant or lactating.
- •Positive results for the urine drug/alcohol breath screen at screening or check-in.
- •Positive urine cotinine at screening or check-in.
- •Participants with the following laboratory abnormalities at screening:
- •ALT or AST >1.0 times ULN
- •Creatinine grade 2 or greater (>1.5 times ULN)
- •Total lipase or amylase >1.0 times ULN
- •Total bilirubin grade 1 or greater (>1.0 times ULN)
- •CPK >1.25 times ULN If exclusionary lab criteria are met, values may be confirmed by repeat evaluation.
- •Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV).
- •Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results at screening.
- •Seated or supine blood pressure is less than 90/40 mmHg or greater than 150/90 mmHg at screening, Day -2 (check-in), Day -1, or pre-dose. Out of range vital signs may be repeated once for confirmation.
- •Out of range values will not be considered AEs if the repeat assessment is in range.
- •Heart rate is lower than 40 bpm or higher than 100 bpm at screening, Day -2 (check-in), Day -1, or pre-dose. Out of range vital signs may be repeated once for confirmation. Out of range values will not be considered AE s if the repeat assessment is in range.
- •Any clinically significant electrocardiogram abnormality at Screening (as deemed by decision of the Investigator and the Sponsor's Medical Monitor).
- •NOTE: The following can be considered not clinically significant without consulting the Sponsor's Medical Monitor:
- •Mild first-degree A-V block (P-R interval <0.23 sec)
- •Right or left axis deviation
- •Incomplete right bundle branch block
- •Isolated left anterior fascicular block (left anterior hemiblock) in younger athletic participants
- •QTcF interval >450 ms for males or >470 ms for females at screening, Day -2, Day -1, or Day 1 (pre-dose), or history of prolonged QT syndrome. For triplicate ECGs taken at screening and Day-2, the average QTcF interval of the three ECG recordings will be used to determine qualification.
- •Family history of Long-QT Syndrome or sudden death without a preceding diagnosis of a condition that could be causative of sudden death (such as known coronary artery disease, congestive heart failure or terminal cancer).
- •Use of any prescription medication within 14 days prior to dosing.
- •Use of any over the counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to dosing, except acetaminophen. Up to 3 grams per day of acetaminophen is allowed at the discretion of the Investigator prior to dosing.
- •Use of any drugs or substances known to be significant inhibitors of Cytochrome P450 (CYP) enzymes and/or significant inhibitors or substrates of P-glycoprotein (P-gp) and/or Organic anion transporting polypeptides (OATP) within 14 days prior to the first dose of trial drug.
- •Use of any drugs or substances known to be inducers of CYP enzymes and/or P-gp, including St. John's Wort, within 30 days prior to the first dose of trial drug.
- •Blood donation or significant blood loss (volume >500 ml) within 56 days prior to dosing.
- •Plasma donation within 7 days prior to dosing.
- •Participation in another clinical trial within 30 days prior to dosing.
- •Has been on a significantly abnormal diet during the 4 weeks preceding the first dose of trial medication.
- •Unwilling to remove any artificial nails (e.g. acrylic, gel) or fingernail polish and not use such products for the duration of the trial.
- •History or presence of allergic or adverse response to Listerine breath strips or aspartame.
- •Additionally, the following exclusion applies only to participants in Part 1, the SAD trial: Is lactose intolerant. - The following food and beverages are not allowed from 72 hours prior to dosing up until the end of the confinement period (discharge from the clinic):
- •Xanthine-containing products (e.g. coffee, tea, cola, chocolate)
- •Alcohol-containing beverages
- •Grapefruit, grapefruit juice, and Seville oranges
- •Beverages containing quinine (e.g. tonic, bitter lemon) Medications that are excluded for inclusion into the trial should remain restricted until the end of the confinement period
研究组 & 干预措施
Single Ascending Dose 25 - 800 mg
Active Comparator
single dose of TBAJ-587
干预措施: TBAJ-587 (Drug)
Single Ascending Dose 25 - 800 mg placebo
Placebo Comparator
single dose of placebo
干预措施: Placebo (Drug)
Multiple Ascending Dose 50 - 200 mg
Active Comparator
28 days dose of TBAJ-587
干预措施: TBAJ-587 (Drug)
Multiple Ascending Dose 50 - 200 mg Placebo
Placebo Comparator
28 days dose of placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants with Treatment-Related Adverse Events in the Single Ascending Dose (SAD) population
时间窗: from date of the start of treatment through completion of clinical procedures on Day 126
Subjects will be monitored for any adverse events from the signing of the consent form until the end-of-study visit. The Investigator or a Sub-Investigator will assess its relationship to the study drug.
Number of Participants with Treatment-Related Adverse Events in the Multiple Ascending Dose (MAD) population
时间窗: from date of the start of treatment through completion of clinical procedures on Day 168
Subjects will be monitored for any adverse events from the signing of the consent form until the end-of-study visit. The Investigator or a Sub-Investigator will assess its relationship to the study drug.
次要结局
- Pharmacokinetics, Maximum concentration (Cmax), of TBAJ-587 and metabolites(Day(D)1: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,16; D2: 24,28,32,36,40,44; D3: 48,54,60,66; D4: 72,78,84,90; D5: 96,108; D6: 120,132; D7: 144,156; D8: 168; D14: 0.5,1,2,3,4,5,6,7,8,12,16,24; D28: 0.5,1,2,3,4,5,6,7,8,12,16,24,36)
- Pharmacokinetics, Time of maximum concentration (Tmax), of TBAJ-587 and metabolites(Day(D)1: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,16; D2: 24,28,32,36,40,44; D3: 48,54,60,66; D4: 72,78,84,90; D5: 96,108; D6: 120,132; D7: 144,156; D8: 168; D14: 0.5,1,2,3,4,5,6,7,8,12,16,24; D28: 0.5,1,2,3,4,5,6,7,8,12,16,24,36)
- Pharmacokinetics, Area under the concentration-time curve (AUC), of TBAJ-587 and metabolites(Day(D)1: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,16; D2: 24,28,32,36,40,44; D3: 48,54,60,66; D4: 72,78,84,90; D5: 96,108; D6: 120,132; D7: 144,156; D8: 168; D14: 0.5,1,2,3,4,5,6,7,8,12,16,24; D28: 0.5,1,2,3,4,5,6,7,8,12,16,24,36)
- Effect of a high-calorie, high-fat meal on the pharmacokinetics of TBAJ-587(Day 1: 0, 0.5, 1, 1,5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16; Day 2: 24, 28, 32, 36, 40, 44; Day 3: 48, 54, 60, 66; Day 4: 72, 78, 84, 90; Day 5: 96, 108; Day 6: 120, 132; Day 7: 144, 156; Day 8: 168)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy AdultsPulmonary DiseaseTuberculosis, PulmonaryMulti Drug Resistant TuberculosisDrug Sensitive TuberculosisTuberculosisMycobacterium Tuberculosis InfectionDrug-resistant TuberculosisNCT04493671Global Alliance for TB Drug Development137
已完成
1 期
Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With PrediabetesSafety IssuesPharmacokineticNCT06378125University Hospital Schleswig-Holstein60
已完成
早期 1 期
A Phase I Study to Evaluate LSALT PeptideNone - Study is to Determine Safety in Healthy ParticipantsNCT03772678Arch Biopartners Inc.52
已完成
1 期
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy AdultsTuberculosis, PulmonaryTuberculosisNCT03758612Global Alliance for TB Drug Development86
已完成
1 期
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy VolunteersHealthyNCT03301298Promentis Pharmaceuticals, Inc.48